Skip to Content

Notice

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of the Immune Response to a Modified Dosing Schedule of the Quadrivalent HPV Vaccine, Potential Extramural Project (PEP) 2007-R-03

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 15698

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Date: 12 p.m.-4 p.m., May 17, 2007 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of “The Immune Response to a Modified Dosing Schedule of the Quadrivalent HPV Vaccine,” PEP 2007-R-03.

Contact Person for More Information: Christine J. Morrison, PhD, Scientific Review Administrator, Office of the Chief Science Officer, CDC, 1600 Clifton Road NE, Mailstop D-72, Atlanta, GA 30333, Telephone (404) 639-3098.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Start Signature

Dated: March 26, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

End Signature End Preamble

[FR Doc. E7-6036 Filed 3-30-07; 8:45 am]

BILLING CODE 4163-18-P